423 related articles for article (PubMed ID: 28276747)
1. Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification.
Fu S; Liu X; Luo M; Xie K; Nice EC; Zhang H; Huang C
Expert Rev Proteomics; 2017 Apr; 14(4):351-362. PubMed ID: 28276747
[TBL] [Abstract][Full Text] [Related]
2. Proteogenomics for understanding oncology: recent advances and future prospects.
Subbannayya Y; Pinto SM; Gowda H; Prasad TS
Expert Rev Proteomics; 2016; 13(3):297-308. PubMed ID: 26697917
[TBL] [Abstract][Full Text] [Related]
3. Current status of clinical proteogenomics in lung cancer.
Nishimura T; Nakamura H; Végvári Á; Marko-Varga G; Furuya N; Saji H
Expert Rev Proteomics; 2019 Sep; 16(9):761-772. PubMed ID: 31402712
[No Abstract] [Full Text] [Related]
4. Proteogenomics: From next-generation sequencing (NGS) and mass spectrometry-based proteomics to precision medicine.
Ang MY; Low TY; Lee PY; Wan Mohamad Nazarie WF; Guryev V; Jamal R
Clin Chim Acta; 2019 Nov; 498():38-46. PubMed ID: 31421119
[TBL] [Abstract][Full Text] [Related]
5. Integrated proteo-genomic approach for early diagnosis and prognosis of cancer.
Shukla HD; Mahmood J; Vujaskovic Z
Cancer Lett; 2015 Dec; 369(1):28-36. PubMed ID: 26276717
[TBL] [Abstract][Full Text] [Related]
6. Onco-proteogenomics: Multi-omics level data integration for accurate phenotype prediction.
Dimitrakopoulos L; Prassas I; Diamandis EP; Charames GS
Crit Rev Clin Lab Sci; 2017 Sep; 54(6):414-432. PubMed ID: 29025326
[TBL] [Abstract][Full Text] [Related]
7. Proteogenomic interrogation of cancer cell lines: an overview of the field.
Tsang O; Wong JWH
Expert Rev Proteomics; 2021 Mar; 18(3):221-232. PubMed ID: 33877947
[No Abstract] [Full Text] [Related]
8. Proteome-wide onco-proteogenomic somatic variant identification in ER-positive breast cancer.
Dimitrakopoulos L; Prassas I; Sieuwerts AM; Diamandis EP; Martens JWM; Charames GS
Clin Biochem; 2019 Apr; 66():63-75. PubMed ID: 30684468
[TBL] [Abstract][Full Text] [Related]
9. Proteogenomics: concepts, applications and computational strategies.
Nesvizhskii AI
Nat Methods; 2014 Nov; 11(11):1114-25. PubMed ID: 25357241
[TBL] [Abstract][Full Text] [Related]
10. Proteogenomics approaches for studying cancer biology and their potential in the identification of acute myeloid leukemia biomarkers.
Hernandez-Valladares M; Vaudel M; Selheim F; Berven F; Bruserud Ø
Expert Rev Proteomics; 2017 Aug; 14(8):649-663. PubMed ID: 28693350
[TBL] [Abstract][Full Text] [Related]
11. Proteogenomics: Key Driver for Clinical Discovery and Personalized Medicine.
Barbieri R; Guryev V; Brandsma CA; Suits F; Bischoff R; Horvatovich P
Adv Exp Med Biol; 2016; 926():21-47. PubMed ID: 27686804
[TBL] [Abstract][Full Text] [Related]
12. Proteogenomic data and resources for pan-cancer analysis.
Li Y; Dou Y; Da Veiga Leprevost F; Geffen Y; Calinawan AP; Aguet F; Akiyama Y; Anand S; Birger C; Cao S; Chaudhary R; Chilappagari P; Cieslik M; Colaprico A; Zhou DC; Day C; Domagalski MJ; Esai Selvan M; Fenyö D; Foltz SM; Francis A; Gonzalez-Robles T; Gümüş ZH; Heiman D; Holck M; Hong R; Hu Y; Jaehnig EJ; Ji J; Jiang W; Katsnelson L; Ketchum KA; Klein RJ; Lei JT; Liang WW; Liao Y; Lindgren CM; Ma W; Ma L; MacCoss MJ; Martins Rodrigues F; McKerrow W; Nguyen N; Oldroyd R; Pilozzi A; Pugliese P; Reva B; Rudnick P; Ruggles KV; Rykunov D; Savage SR; Schnaubelt M; Schraink T; Shi Z; Singhal D; Song X; Storrs E; Terekhanova NV; Thangudu RR; Thiagarajan M; Wang LB; Wang JM; Wang Y; Wen B; Wu Y; Wyczalkowski MA; Xin Y; Yao L; Yi X; Zhang H; Zhang Q; Zuhl M; Getz G; Ding L; Nesvizhskii AI; Wang P; Robles AI; Zhang B; Payne SH;
Cancer Cell; 2023 Aug; 41(8):1397-1406. PubMed ID: 37582339
[TBL] [Abstract][Full Text] [Related]
13. Identification of Differentially Expressed Splice Variants by the Proteogenomic Pipeline Splicify.
Komor MA; Pham TV; Hiemstra AC; Piersma SR; Bolijn AS; Schelfhorst T; Delis-van Diemen PM; Tijssen M; Sebra RP; Ashby M; Meijer GA; Jimenez CR; Fijneman RJA
Mol Cell Proteomics; 2017 Oct; 16(10):1850-1863. PubMed ID: 28747380
[TBL] [Abstract][Full Text] [Related]
14. Molecular insights into cancer drug resistance from a proteomics perspective.
An Y; Zhou L; Huang Z; Nice EC; Zhang H; Huang C
Expert Rev Proteomics; 2019 May; 16(5):413-429. PubMed ID: 30925852
[TBL] [Abstract][Full Text] [Related]
15. Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine.
Joshi SK; Piehowski P; Liu T; Gosline SJC; McDermott JE; Druker BJ; Traer E; Tyner JW; Agarwal A; Tognon CE; Rodland KD
Annu Rev Pharmacol Toxicol; 2024 Jan; 64():455-479. PubMed ID: 37738504
[TBL] [Abstract][Full Text] [Related]
16. Current Challenges and Implications of Proteogenomic Approaches in Prostate Cancer.
Shukla N; Siva N; Malik B; Suravajhala P
Curr Top Med Chem; 2020; 20(22):1968-1980. PubMed ID: 32703135
[TBL] [Abstract][Full Text] [Related]
17. Linking cancer genome to proteome: NCI's investment into proteogenomics.
Rivers RC; Kinsinger C; Boja ES; Hiltke T; Mesri M; Rodriguez H
Proteomics; 2014 Dec; 14(23-24):2633-6. PubMed ID: 25187343
[TBL] [Abstract][Full Text] [Related]
18. Proteogenomic Tools and Approaches to Explore Protein Coding Landscapes of Eukaryotic Genomes.
Kumar D; Dash D
Adv Exp Med Biol; 2016; 926():1-10. PubMed ID: 27686802
[TBL] [Abstract][Full Text] [Related]
19. PepQuery enables fast, accurate, and convenient proteomic validation of novel genomic alterations.
Wen B; Wang X; Zhang B
Genome Res; 2019 Mar; 29(3):485-493. PubMed ID: 30610011
[TBL] [Abstract][Full Text] [Related]
20. Methods, Tools and Current Perspectives in Proteogenomics.
Ruggles KV; Krug K; Wang X; Clauser KR; Wang J; Payne SH; Fenyö D; Zhang B; Mani DR
Mol Cell Proteomics; 2017 Jun; 16(6):959-981. PubMed ID: 28456751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
